ArQule says partner halts cancer drug trial, shares slide
(Reuters) – Biotechnology company ArQule Inc said Japan’s Kyowa Hakko Kirin Co, which holds development rights to an ArQule cancer drug in parts of Asia, suspended patient enrollment in a late-stage trial to treat lung cancer. Shares of Woburn, Massachusetts-based ArQule fell 28 percent to a more than 9-month low of $4. 81 on the Nasdaq on Wednesday. The stock, which was the biggest percentage loser on the exchange, later recouped some of the losses to trade down at $5. 25. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply